Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.

about

Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.

Item

http://www.wikidata.org/entity/Q47700645

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.

@en

Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.

@nl

type

Item

label

Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.

@en

Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.

@nl

prefLabel

Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.

@en

Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.

@nl

P1476

Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.

@en

P2093

Célio Fernando de Sousa-Rodrigues

http://www.w3.org/2001/XMLSchema#string

Fabiano Timbó Barbosa

http://www.w3.org/2001/XMLSchema#string

Fernando José Camello de Lima

http://www.w3.org/2001/XMLSchema#string

Leyna Leite Santos

http://www.w3.org/2001/XMLSchema#string

P2860

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

SGLT2 inhibitors in the treatment of type 2 diabetes.

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

SGLT2 mediates glucose reabsorption in the early proximal tubule.

Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.

Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes.

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.

P304

636-641

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1590/1806-9282.63.07.636

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28977090

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes